Turalio: Why The EU Said No To The US-Approved Drug
The EU Rejected The Drug A Year After Its US Approval
Not everyone reviewing Daiichi Sankyo’s EU marketing application for Turalio agreed that the potential tenosynovial giant cell tumor treatment shouldn't be approved.
